InspireMD Boosts MGuard Production CapacityBy Inspiremd, PRNE
Tuesday, March 1, 2011
Production Capacity of MGuard, the Unique Thrombus Management Stent System, Will Double in 2011 to Meet Steady Increase in Demand
TEL AVIV, Israel, March 2, 2011 - InspireMD (www.inspire-md.com/site_en/), developer of
the MGuard(TM) net protective stent system (
www.inspire-md.com/site_en/mguard/the-technology/), has expanded its
MGuard production facilities to meet the steady increase in demand. The
driving forces behind the accelerating demand for MGuard include the recent
recommendation of the European Society of Cardiology (ESC) mesh-based
protection to be considered for PCI of highly thrombotic or SVG lesions.
Currently, this type of approved mesh technology is exclusively produced by
InspireMD in its unique MGuard(TM) mesh protected coronary stent system.
Greater awareness of the MGuard solution among interventional cardiologists
worldwide has been contributing to increased MGuard sales. To accommodate
this increased demand, InspireMD has enlarged its production workforce and
invested in new crimping machinery that can double InspireMD's previous
"Based on our last published financial results, for the nine
months ended September 30, 2010, our sales have increased more than 100%
compared to the same period in 2009, and with this growth in mind, we have
expanded to meet increased production demand," said Eli Bar, CTO and VP R&D
at InspireMD. "When we evaluated the success criteria for our investment in
advanced crimping machinery, it was important to us that we would be able to
increase production capacity by a factor of two. With our expanded
facilities, we have experienced an even larger increase of our production
capacity, and we are able to achieve constant output of a homogenous product
of optimal quality."
"One of the main success factors of our business is our
ability to produce and deliver our high quality products to match demand,"
stated Ofir Paz, CEO of InspireMD. "We are very pleased to see that our
MGuard solution is becoming widely accepted as the preferred alternative for
thrombus management in heart attack patients. The current expansion is the
beginning of a major expansion in our production designed to meet the
continued upward demand for MGuard solutions worldwide.
About MGuard(TM) Coronary
MGuard(TM) presents a novel combination of a coronary stent
merged with an embolic protection specifically designed for Acute MI
patients. The embolic protection is comprised of an ultra-thin polymer mesh
sleeve that wraps the stent. The MGuard(TM) coronary stent provides permanent
embolic protection, without affecting deliverability. MGuard(TM) is CE Mark
approved. Mesh-based protection is now recommended for use in the recent
Guidelines of the Task force of Myocardial Revascularization of the European
Society of Cardiology (ESC). The MGuard(TM) innovative concept has enjoyed an
enthusiastic welcome from leading interventional cardiologists around the
About InspireMD Ltd.
InspireMD is an innovative medical device company focusing on
the development and commercialization of its proprietary stent system
technology, MGuard(TM). InspireMD intends to pursue applications of this
technology in coronary, carotid and peripheral artery procedures.
Contact details: Jonina Ohayon Marketing Director firstname.lastname@example.org +972-52-5791120
Jonina Ohayon, Marketing Director, jonina at inspire-md.com , +972-52-5791120
Tags: InspireMD, Israel, March 2, Tel aviv